Enliven Therapeutics announces FDA alignment on Phase 3 relcobatinib CML trial design, expects start before year-end

Enliven Therapeutics announced FDA alignment on the Phase 3 relcobatinib chronic myeloid leukemia trial design and expects the trial to start before year-end.

Detected & updated continuously · Source: Nebula